Figure S4 from Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer
Matthew D. Galsky, Mark Kockx, Juliette Roels, Roos Van Elzen et autres
Figure S4
0 citations
Sandrine Bernhard
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
20Publications signalées
1008Citations signalées
0Affiliations récentes
Les domaines associés
Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and BiomarkersUrinary and Genital Oncology StudiesFerroptosis and cancer prognosisIntraperitoneal and Appendiceal Malignancies
Les publications récentes
Figure S3 from Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer
Matthew D. Galsky, Mark Kockx, Juliette Roels, Roos Van Elzen et autres
FigS3
0 citations
Figure S1 from Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer
Matthew D. Galsky, Mark Kockx, Juliette Roels, Roos Van Elzen et autres
FigS1
0 citations
Figure S2 from Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer
Matthew D. Galsky, Mark Kockx, Juliette Roels, Roos Van Elzen et autres
Fig S2
0 citations
Figure S4 from Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer
Matthew D. Galsky, Mark Kockx, Juliette Roels, Roos Van Elzen et autres
Figure S4
0 citations
Figure S1 from Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer
Matthew D. Galsky, Mark Kockx, Juliette Roels, Roos Van Elzen et autres
FigS1
0 citations
Data from Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer
Matthew D. Galsky, Mark Kockx, Juliette Roels, Roos Van Elzen et autres
Abstract Testing for PD-L1 expression by IHC is used to predict immune checkpoint blockade (ICB) benefits but has performed inconsistently in urothelial cancer clinical trials. Different approaches are used for PD-L1 IHC. We analyzed paired PD-L1 IHC data on urothelial cancer samples …
0 citations
Figure S3 from Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer
Matthew D. Galsky, Mark Kockx, Juliette Roels, Roos Van Elzen et autres
FigS3
0 citations
Table S1 from Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer
Matthew D. Galsky, Mark Kockx, Juliette Roels, Roos Van Elzen et autres
TableS1
0 citations
Figure S2 from Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer
Matthew D. Galsky, Mark Kockx, Juliette Roels, Roos Van Elzen et autres
Fig S2
0 citations
Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer
Matthew D. Galsky, Mark Kockx, Juliette Roels, Roos Van Elzen et autres
Testing for PD-L1 expression by IHC is used to predict immune checkpoint blockade (ICB) benefits but has performed inconsistently in urothelial cancer clinical trials. Different approaches are used for PD-L1 IHC. We analyzed paired PD-L1 IHC data on urothelial cancer samples using …
us, be, se, gr, es, jp, de, at, au, gb (code pays fourni par la source)
6 citations
Cancer Immunology Research
Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer
Matthew D. Galsky, Xiangnan Guan, Deepali Rishipathak, Aaron S. Rapaport et autres
In metastatic urothelial cancer (mUC), cisplatin versus carboplatin leads to durable disease control in a subset of patients. The IMvigor130 trial reveals more favorable effects with atezolizumab combined with gemcitabine and cisplatin (GemCis) versus gemcitabine and carboplatin (GemCarbo). This study investigates the …
us, ca, gr, at, de, au, es, jp, gb, fr (code pays fourni par la source)
59 citations
Cell Reports Medicine
BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.